Misonix Incorporated

349 articles about Misonix Incorporated

• Bioventus Completes the Acquisition of Misonix

  10/29/2021

  Bioventus Inc. has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock.

• Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results

  9/2/2021

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021.

• Misonix Reports Preliminary Fiscal 2021 Fourth Quarter and Full Year Revenue ResultsCompany Enters into a Definitive Merger Agreement to be Acquired by Bioventus for $518 Million in a Cash-and-Stock Transaction

  7/29/2021

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes announced preliminary unaudited fiscal 2021 fourth quarter and full year revenue results for the three- and twelve-month periods ended June 30, 2021.

• Misonix Appoints Patrick J. Beyer to Board of DirectorsLeading Medical Tech Executive Brings Extensive Industry Knowledge, Strategic Leadership and Financial Expertise to Board

  5/14/2021

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board.

• Misonix to Participate in Upcoming May and June Virtual Investor Conferences

  5/10/2021

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Chief Executive Officer, Stavros Vizirgianakis, along with Chief Financial Officer, Joe Dwyer, will be participating in the following upcoming virtual investor conferences in May and June

• Misonix Reports Fiscal 2021 Third Quarter Financial ResultsMisonix Raises Guidance for neXus® Ultrasonic Surgical System to 200 Unit Placements by Fiscal 2021 Year-End

  5/6/2021

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported financial results for the fiscal 2021 third quarter ended March 31, 2021

• Misonix to Report Fiscal 2021 Third Quarter Financial Results and Host Conference Call and Webcast on May 6

  4/20/2021

  Misonix, Inc.  (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 third quarter financial results after the market closes on Thursday, May 6, 2021.

• Misonix to Participate in Upcoming March Investor Conferences

  3/1/2021

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Cowen 41 st Annual Healthcare Conference and the Oppenheimer 31 st Annual Healthcare Conference on March 4 th and March 16 th , respectively.

• Misonix to Participate at Upcoming Investor Conferences

  2/11/2021

  Misonix, Inc.  (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be participating in two upcoming investor conferences. BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference Dates: F

• Misonix to Report Fiscal 2021 Second Quarter Financial Results and Host Conference Call and Webcast on February 4

  1/21/2021

  Misonix, Inc.  (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 second quarter financial results after the market closes on Thursday, February 4, 2021. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the g

• Misonix to Present at the 39th Annual J.P. Morgan Healthcare Conference

  12/23/2020

  Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 39 th Annual J.P. Morgan Healthcare Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Thursday, January 14

• Misonix Announces the Second Largest U.S. Commercial Payer Has Provided Coverage for TheraSkin® to Treat All Lower Extremity Dermal Wounds Adding 32 Million New Covered Lives

  12/18/2020

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that the second largest U.S. Commercial payer will now cover Thera S kin for all lower extremity dermal wounds. TheraSkin is a proven cellular and tissue-based treatment for difficult to heal chronic wounds. “This favorable decision by the second larges

• Misonix to Participate at Upcoming Craig-Hallum and Canaccord Genuity Investor Conferences

  11/12/2020

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Craig-Hallum and Canaccord Genuity investor conferences in November. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be available to host one-on-one meetings with

• Misonix Fiscal 2021 First Quarter Revenue Rises 59% to $17.7 Million

  11/5/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, reported unaudited financial results for the fiscal 2021 first quarter ended September 30, 2020 as summarized below:

• Misonix to Report Fiscal 2021 First Quarter Financial Results and Host Conference Call and Webcast on November 5

  10/20/2020

  Misonix, Inc.  (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2021 first quarter financial results after the market closes on Thursday, November 5, 2020. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the ge

• Misonix Reports Preliminary Fiscal 2021 First Quarter Revenue of Approximately $17.7 MillionConfirms Improving Revenue Trends, Rise in Procedure Volumes and Strong New Product Adoption

  10/6/2020

  Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced preliminary unaudited revenue for the first quarter of its fiscal year 2021 ended September 30, 2020.

• Misonix Enters Into Exclusive Supply and Distribution Agreement With Gunze Limited for TheraGenesis® Bilayer Wound MatrixExpands Misonix’s Wound Tissue Regeneration Franchise and Complements Nexus SonicOne® Strategy

  9/21/2020

  Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products that enhance clinical outcomes, announced today that it has entered into an exclusive supply and distribution agreement with Gunze Limited for TheraGenesis ® Bilayer Wound Matrix. TheraGenesis is a proprietary, FDA cleared, porcine tendon derived collagen wound matrix with a silicone film layer

• Misonix to Present at the Cantor Virtual Global Healthcare Conference

  9/9/2020

  Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the Cantor Virtual Global Healthcare  Conference.

• Misonix Reports Fourth Quarter and Fiscal Year 2020 Results

  9/3/2020

  Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2020 fourth quarter and full fiscal year ended June 30, 2020 as summarized below:   Three Months Ended   Year Ended   June 30,   June 30,     2020     2019       2020

• Misonix to Report Fiscal 2020 Fourth Quarter Financial Results and Host Conference Call and Webcast on September 3

  8/6/2020

  Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2020 fourth quarter financial results after the market closes on Thursday, September 3, 2020. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to th